LogoLogo
  • What is IHCI?
  • 5 Components
  • Publications
    • IHCI: Publication on Simple app on SAGE Digital Health
    • IHCI: Blood Pressure Control Using Drug and Dose-Specific Standard Treatment Protocol
    • IHCI–Early outcomes in 26 districts across five states of India
    • IHCI—Hypertension treatment and blood pressure control in a cohort
    • IHCI—Interventions to Ensure the Continuum of Care for Hypertension During the COVID-19 Pandemic
    • IHCI—Improving the availability of antihypertensive drugs in IHCI, 2019–2020
  • Events
  • Resources
    • IHCI Progress Brief 2022
    • State Hypertension Protocols
    • Training Modules
    • Simple App
    • BP Measurement Checklists
    • IEC Materials
      • IHCI Factsheet
      • Hypertension Myths and Facts
      • Hypertension Best Practices
  • About
    • Contact Us
    • Teams
      • Core Team
      • Support Team
      • State and District Team
    • Governance Mechanism
Powered by GitBook
On this page

Was this helpful?

Export as PDF
  1. Publications

IHCI—Improving the availability of antihypertensive drugs in IHCI, 2019–2020

PreviousIHCI—Interventions to Ensure the Continuum of Care for Hypertension During the COVID-19 PandemicNextEvents

Last updated 9 months ago

Was this helpful?

Kunwar A, Kaur P, Durgad K, Parasuraman G, Sharma M, et al. (2023). . PLOS ONE 18(12): e0295338.

December 14, 2023

Background

Antihypertensive drug supply is sometimes inadequate in public sector health facilities in India. One of the core strategies of the India Hypertension Control Initiative (IHCI) is to improve the availability of antihypertensive drugs in primary and secondary care facilities. We quantified the availability of antihypertensive drugs in 2019–20 and described the practices in supply chain management in 22 districts across four states of India.

Methods

Twenty-two districts from 4 states (Punjab, Madhya Pradesh, Telangana, and Maharashtra) were studied. We described the practices and challenges in supply chain management. We collected data on drug procurement from 2018 to 2020 and drug availability from April 2019 to March 2020. Quantity procured, the proportion of facilities with stockout at the end of each quarter, and availability of drugs in patient days were tabulated.

Results

All states selected drug- and dose-specific protocols with Amlodipine as the initial drug and shifted to morbidity-based forecasting. The total number of antihypertensive tablets procured for the 22 districts increased from 16 million in 2017–2018 to 160 million in 2019–2020. The proportion of facilities with Amlodipine stock-out was below 5% during the study period. Amlodipine stock was available for at least 60 patient days from the third quarter of 2019 onward in all districts.

Conclusions

This study demonstrates that including best practices can gradually strengthen the procurement and supply chain for antihypertensives in a low-resource setting. As the program was rapidly growing, there were still gaps in the procurement and distribution system which needed to be addressed to ensure the adequacy of drugs. We recommend that best practices, including choosing a single protocol, basing supply on projected patient load rather than an increment from historical levels, and using simple stock management tools, be replicated in other districts in India to increase and sustain coverage of hypertension treatment.

Improving the availability of antihypertensive drugs in the India Hypertension Control Initiative, India, 2019–2020
https://doi.org/10.1371/journal.pone.0295338